Want to see HK:9955 full AI Analyst Report?
9955 Stock Chart & Stats
HK$1.00
HK$0.03(2.52%)
At close: 4:00 PM EST
HK$1.00
HK$0.03(2.52%)
Day’s Range― - ―
52-Week RangeHK$0.49 - HK$1.80
Previous CloseN/A
Volume146.50K
Average Volume (3M)1.09M
Market Cap
HK$360.32M
Enterprise ValueHK$332.69M
Total Cash (Recent Filing)HK$445.29M
Total Debt (Recent Filing)HK$558.23M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.60
Shares Outstanding645,718,800
10 Day Avg. Volume899,970
30 Day Avg. Volume1,090,236
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.00
Price to Sales (P/S)0.34
P/FCF Ratio-8.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.11
Revenue Forecast (FY)HK$7.73B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StabilizationThe move to positive equity and a moderate debt-to-equity (~0.53 in 2025) signals a more normalized capital structure versus prior negative-equity years. This durable improvement lowers insolvency risk, preserves access to credit, and provides structural capacity to support operations and strategic investments if losses moderate.
Operating Cash Flow RecoveryA return to positive operating cash flow (~82M in 2025) reflects improved cash generation from core operations and reduces reliance on external financing. This structural improvement enhances liquidity management, supports near-term working-capital needs, and creates a firmer base to fund restructuring or efficiency initiatives over the medium term.
Material Gross Margin ImprovementA sustained uplift in gross margin (to ~48% in 2025 from ~25% earlier) indicates meaningful improvement in pricing, product mix, or procurement. Higher structural gross margins create more room to absorb fixed costs and support a pathway to operating leverage and eventual profitability if revenue trends stabilize or recover.
Bears Say
Sharp Revenue ContractionA ~30% revenue decline in 2025 materially erodes scale economics and supplier negotiating leverage. Persistently lower top-line volumes strain fixed-cost absorption, make margin gains harder to convert into operating profit, and indicate structural demand loss or competitive displacement that could impede recovery over months.
Large Net Losses RemainDeep net losses (net margin ~-57% in 2025) erode retained capital and hinder reinvestment. Sustained operating deficits damage return metrics and shareholder equity over time, limit management flexibility, and increase the likelihood of needing dilutive financing or cost cuts that could impair long-term growth prospects.
Negative Free Cash FlowNegative free cash flow (~-65M in 2025) means the business is not self-funding after investments and working-capital needs. This structural cash shortfall necessitates external funding, constrains capital allocation decisions, and raises execution risk for growth or margin initiatives if capital markets tighten.
ClouDr Group Limited News
9955 FAQ
What was ClouDr Group Limited’s price range in the past 12 months?
ClouDr Group Limited lowest stock price was HK$0.49 and its highest was HK$1.80 in the past 12 months.
What is ClouDr Group Limited’s market cap?
ClouDr Group Limited’s market cap is HK$360.32M.
When is ClouDr Group Limited’s upcoming earnings report date?
ClouDr Group Limited’s upcoming earnings report date is Aug 14, 2026 which is in 43 days.
How were ClouDr Group Limited’s earnings last quarter?
ClouDr Group Limited released its earnings results on Mar 26, 2026. The company reported -HK$0.636 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.636.
Is ClouDr Group Limited overvalued?
According to Wall Street analysts ClouDr Group Limited’s price is currently Overvalued.
Does ClouDr Group Limited pay dividends?
ClouDr Group Limited does not currently pay dividends.
What is ClouDr Group Limited’s EPS estimate?
ClouDr Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ClouDr Group Limited have?
ClouDr Group Limited has 645,718,800 shares outstanding.
What happened to ClouDr Group Limited’s price movement after its last earnings report?
ClouDr Group Limited reported an EPS of -HK$0.636 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.154%.
Which hedge fund is a major shareholder of ClouDr Group Limited?
Currently, no hedge funds are holding shares in HK:9955
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ClouDr Group Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.34%
12-Months-Change
Fundamentals
Return on Equity
-66.54%
Trailing 12-Months
Asset Growth
-38.03%
Trailing 12-Months
Company Description
ClouDr Group Limited
ClouDr Group Limited operates as an investment holding company, providing a diverse range of services within the healthcare sector. The firm supplies hospitals and pharmacies with crucial medical products, including devices like blood glucose meters and vital sign monitors, glucose testing strips, and both over-the-counter and prescription drugs. In addition to physical goods, ClouDr delivers software-as-a-service (SaaS) platforms tailored for healthcare facilities and pharmacies, while also offering digital marketing solutions to pharmaceutical companies. Furthermore, the company facilitates the management of chronic conditions through real-time online consultations, digital health monitoring, and remote prescription and ordering services. Established in 2014, ClouDr Group Limited maintains its primary corporate office in Hangzhou, China.
Technical Analysis
China Health Group
―
Sinopharm Group Co
―
IVD Medical Holding Limited
―
Medlive Technology Co., Ltd.
―
Charmacy Pharmaceutical Co., Ltd. Class H
―
Options Prices
Currently, No data available
---